News iBio, Inc.

Equities

IBIO

US4510337086

Real-time Estimate Cboe BZX Other stock markets 01:42:04 2024-04-25 pm EDT			5-day change	1st Jan Change
1.77 ^USD	-6.84%		-0.03%	+29.15%

Apr. 01	IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors	CI
Mar. 28	Top Premarket Gainers	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors	Mar. 31	CI
Top Premarket Gainers	Mar. 28	MT
Top Midday Gainers	Mar. 27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	Mar. 27	MT
Transcript : IBio, Inc. - Special Call	Mar. 27
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings	Mar. 27	MT
Top Premarket Gainers	Mar. 27	MT
IBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases	Mar. 27	AQ
IBio, Inc. and AstralBio, Inc. Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases	Mar. 27	CI
IBio Announces $15.0 Million Private Placement	Mar. 26	AQ
IBio, Inc. announced that it has received $14 million in funding	Mar. 25	CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	Feb. 26	DJ
IBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka	Feb. 26	AQ
Otsuka Pharmaceutical Co., Ltd. completed the acquisition of Preclinical PD-1 Agonist Antibody Program of iBio, Inc..	Feb. 24	CI
IBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 09	CI
IBio Announces Participation in 23rd Annual PepTalk Conference	Jan. 16	AQ
IBio Amends and Extends Maturity of Credit Agreement	Dec. 26	AQ
Top Midday Decliners	Dec. 05	MT
IBio, Inc. Announces Pricing of $4.5 Million Public Offering	Dec. 05	AQ
Top Premarket Decliners	Dec. 05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News iBio, Inc.

Equities

IBIO

US4510337086

Summary

Filters